Two executives sell shares. ANI Pharmaceuticals, Inc. (ANIP) insiders Thomas Andrew Rowland, SVP and Head of Established Brands, and Christopher Mutz, Head of Rare Disease, sold a combined 7,934 shares worth $584,000 in transactions filed March 13, 2026. Rowland offloaded 4,772 shares at $74.91 per share for proceeds of $357,471, while Mutz sold 3,162 shares at $71.64 per share, totaling $226,526.
Selling pattern continues. The dual sales extend an 18-month trend of net insider selling at ANI Pharmaceuticals. Over the past 18 months, insiders have sold 531,712 shares with zero purchases, resulting in net selling of 531,712 shares. The recent transactions represent roughly 1.5% of that total selling activity.
Substantial holdings remain. Following his sale, Rowland retains ownership of 38,730 shares, while Mutz holds 91,309 shares. The price differential between the two transactions—Rowland’s $74.91 versus Mutz’s $71.64—suggests the sales occurred on different days or through different execution methods, though both were reported in the same SEC filing batch.
Institutional ownership concentrated. BlackRock Inc. leads institutional holders with 2.66 million shares representing a nominal fraction of its portfolio, followed by Vanguard Group with 1.31 million shares. Millennium Management increased its stake by 727% to 539,665 shares, providing a counterpoint to the insider selling trend.
aph?
.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.